Show simple item record

dc.contributor.authorLee, Joo-Young
dc.contributor.authorHunt, Paul
dc.date.accessioned2012-10-31T21:19:22Z
dc.date.available2012-10-31T21:19:22Z
dc.date.issued2012
dc.identifier.citationLee, J.-Y. and Hunt, P. (2012), Human rights responsibilities of pharmaceutical companies in relation to access to medicines. The Journal of Law, Medicine & Ethics, 40(2), 220-233.en_NZ
dc.identifier.issn1748-720X
dc.identifier.urihttp://hdl.handle.net/10289/6772
dc.description.abstractAlthough access to medicines is a vital feature of the right to the highest attainable standard of health (“right to health”), almost two billion people lack access to essential medicines, leading to immense avoidable suffering. While the human rights responsibility to provide access to medicines lies mainly with States, pharmaceutical companies also have human rights responsibilities in relation to access to medicines. This article provides an introduction to these responsibilities. It briefly outlines the new UN Guiding Principles on Business and Human Rights and places the human rights responsibilities of pharmaceutical companies in this context. The authors draw from the work of the first UN Special Rapporteur on the right to the highest attainable standard of health, in particular the Human Rights Guidelines for Pharmaceutical Companies in Relation to Access to Medicines that he presented to the UN General Assembly in 2008, and his UN report on GlaxoSmithKline (GSK). While the Guiding Principles on Business and Human Rights are general human rights standards applicable to all business entities, the Human Rights Guidelines for Pharmaceutical Companies consider the specific human rights responsibilities of one sector (pharmaceutical companies) in relation to one area of activity (access to medicines). The article signals the human rights responsibilities of all pharmaceutical companies, with particular attention to patent-holding pharmaceutical companies. Adopting a right-to-health “lens,” the article discusses GSK and accountability. The authors argue that human rights should shape pharmaceutical companies' policies, and provide standards in relation to which pharmaceutical companies could, and should, be held accountable. They conclude that it is now crucial to devise independent, accessible, transparent, and effective mechanisms to monitor pharmaceutical companies and hold them publicly accountable for their human rights responsibilities.en_NZ
dc.language.isoen
dc.relation.urihttp://onlinelibrary.wiley.com/doi/10.1111/j.1748-720X.2012.00660.x/abstract
dc.titleHuman rights responsibilities of pharmaceutical companies in relation to access to medicinesen_NZ
dc.typeJournal Articleen_NZ
dc.identifier.doi10.1111/j.1748-720X.2012.00660.xen_NZ
dc.relation.isPartOfThe Journal of Law, Medicine & Ethics
pubs.begin-page220
pubs.end-page233
pubs.issue2
pubs.volume40


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record